1. |
Kurosaki F, Bando M, Nakayama M, et al. Clinical features of pulmonary aspergillosis associated with interstitial pneumonia. Intern Med, 2014, 53:1299-1306.
|
2. |
American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med, 2002, 165:277-304.
|
3. |
Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis:clinical practice guidelines of the Infectious Diseases Society of America. Clinical infectious diseases:an official publication of the Infectious Diseases Society of America. Clin Infect Dis, 2008, 46:327-360.
|
4. |
中华医学会呼吸病学分会感染学组, 中华结核和呼吸杂志编辑委员会.肺真菌病诊断和治疗专家共识.中华结核和呼吸杂志, 2007, 30:821-834.
|
5. |
Steinbach WJ, Marr KA, Anaissie EJ, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect, 2012, 65:453-464.
|
6. |
Menzin J, Meyers JL, Friedman M, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm, 2009, 66:1711-1717.
|
7. |
Cadena J, Thompson GR 3rd, Patterson TF. Invasive Aspergillosis:current strategies for diagnosis and management. Infect Dis Clin North Am, 2016, 30:125-142.
|
8. |
Caston JJ, Linares MJ, Rivero A, et al. Clinical factors associated with invasive pulmonary aspergillosis in patients with chronic pneumopathies and respiratory isolation of Aspergillus spp. Med Clin, 2012, 139:668-671.
|
9. |
Mosquera RA, Estrada L, Clements RM, et al. Early diagnosis and treatment of invasive pulmonary aspergillosis in a patient with cystic fibrosis. BMJ Case Rep, 2013, 2013.
|
10. |
Wessolossky M, Welch VL, Sen A, et al. Invasive Aspergillus infections in hospitalized patients with chronic lung disease. Infect Drug Resist, 2013, 6:33-39.
|
11. |
Hagiya H, Miyake T, Kokumai Y, et al. Co-infection with invasive pulmonary aspergillosis and Pneumocystis jirovecii pneumonia after corticosteroid therapy. J Infect Chemother, 2013, 19:342-347.
|
12. |
Yang J, Lu Q, Liu W, et al. Cyclophosphamide reduces dectin-1 expression in the lungs of naive and Aspergillus fumigatus-infected mice. Med Mycol, 2010, 48:303-309.
|
13. |
Kolwijck E, van de Veerdonk FL. The potential impact of the pulmonary microbiome on immunopathogenesis of Aspergillus-related lung disease. Eur J Immunol, 2014, 44:3156-3165.
|
14. |
Mowat E, Rajendran R, Williams C, et al. Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation. FEMS Microbiol Lett, 2010, 313:96-102.
|
15. |
Seidler MJ, Salvenmoser S, Muller FM. Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. Antimicrob Agents Chemother, 2008, 52:4130-4136.
|
16. |
Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. New Engl J Med, 2011, 364:1503-1512.
|
17. |
Hu R, Jiang XY, Wu Y. Risk factors for invasive pulmonary fungal infection in patients with hematological malignancies not receiving hematopoietic stem cell transplant. Neoplasma, 2012, 59:669-675.
|